These developments might be helpful only if equal access to the technologies is provided to all the manufacturers and more importantly, these should be provided to multiple manufacturers especially those from low-income countries. For this, discussions were also made to fairly exchange the technologies provided by WHO for the vaccine prototypes that were in phase I or II clinical trials. However, this discussion faced a lot of backlash as the companies did not agree to share their intellectual property. Moreover, some countries did not afford the next-generation vaccines for their programs of national vaccination . Furthermore, several questions exist regarding the global deployment of universal vaccines required for maximizing its benefits and minimized the unintentional consequences. Recently, a review has